Managed Access Programs for INC424, Ruxolitinib

Sponsor
Novartis Pharmaceuticals
Study ID
NCT04745637
Status
Available

Conditions

  • Polycythemia Vera (PV)
  • Post Polycythemia Myelofibrosis (PPV MF)
  • Primary Myelofibrosis (PMF)
  • Severe/Very Severe COVID-19 Illness
  • Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)
  • Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)
  • Thrombocythemia Myelofibrosis (PET-MF)

Eligibility Criteria

Sex
ALL
Age
2 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

Key Dates

Status verified
Oct 2025

Central Contacts

  • MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs
    1-88-669-6682
    [email protected]
  • Novartis Pharmaceuticals
    +41613241111

Related Studies